a b s t r a c t
Cancer and senescence are both complex transformative processes that dramatically alter many features of cell physiology and their interactions with surrounding tissues. Developing the wide range of cellular features characteristic of these conditions requires profound alterations in global gene expression patterns, which can be achieved by suppressing, activating, or uncoupling cellular gene regulatory pathways. Many genes associated with the initiation and development of tumors are regulated at the level of mRNA decay, frequently through the activity of AU-rich mRNA-destabilizing elements (AREs) located in their 3 -untranslated regions. As such, cellular factors that recognize and control the decay of ARE-containing mRNAs can influence tumorigenic or senescent phenotypes mediated by products of these transcripts. In this review, we discuss evidence showing how suppressed expression and/or activity of the ARE-binding protein tristetraprolin (TTP) can contribute to these processes. Next, we outline current findings linking TTP suppression to exacerbation of individual tumorigenic phenotypes, and the roles of specific TTP substrate mRNAs in mediating these effects. Finally, we survey potential mechanisms that cells may employ to suppress TTP expression in cancer, and propose potential diagnostic and therapeutic strategies that may exploit the relationship between TTP expression and tumor progression or senescence.
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Hallmarks and progression of cancer

The diverse cellular features of cancer
Decades of research have defined cancer as a disease caused by dynamic changes in the genome. Mutations acquired familially or accumulated over time can activate oncogenes through dominant gain of function and disable tumor suppressor genes by recessive loss of function (Hanahan and Weinberg, 2011) . The unstable genome of a tumor cell not only makes cancer unique to each patient, but also provides a mechanism by which a single tumor can be heterogeneous in composition. This pathological heterogeneity in turn complicates strategies for early detection and optimal treatment of many cancers, prompting research efforts to identify biomarkers and cellular mechanisms associated with oncogenic transformation and tumor development that may be exploited for therapeutic intervention.
Although cancers display diverse characteristics among different tissues and individuals, there are several common cellular phenotypes that are acquired during the development and progression of the disease. Six of these "cancer hallmarks" were described (Hanahan and Weinberg, 2000) . More recently, the development of a sustained pro-inflammatory tumor microenvironment has been accepted as a seventh hallmark of cancer (Colotta et al., 2009 ). Finally, recently identified biological features that drive cancer development were introduced as "emerging hallmarks" in a comprehensively updated review by Hanahan and Weinberg. These were: [i] deregulation of cellular energetics, [ii] genome instability and mutation, and [iii] avoidance of immune detection (Hanahan and Weinberg, 2011) . Following from this model, a major focus of current cancer research is to identify specific genetic mechanisms and pathways responsible for the acquisition and manifestation of these tumorigenic phenotypes, which subsequently may provide potential targets for downstream therapeutic development.
Oncogenes and pathway deregulation
Cancer is caused primarily by somatic mutations of protooncogenes, proteins whose mutation or uncontrolled expression will initiate a neoplastic transformation (Croce, 2008) . A protooncogene can be activated into an oncogene through a myriad of mechanisms including structural alterations, gene fusions, juxtaposition with enhancers, or amplification (Konopka et al., 1985; Tsujimoto et al., 1985) . This initial mutation can ultimately lead
